USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended April 3, 1999. USANA Health Sciences Inc. develops and manufactures nutritional, personal care, and weight management products distributed via a network marketing system. As of the period end, the company operated in the United States, Canada, Australia/New Zealand, and the United Kingdom, with approximately 118,000 current distributors and 30,000 Preferred Customers.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Net Sales | $31.3 million | $26.2 million |
| Gross Profit | $24.9 million | $20.7 million |
| Net Earnings | $2.1 million | $1.9 million |
| Diluted EPS | $0.16 | $0.14 |
| Cash and Equivalents | $3.4 million | $2.6 million (Jan 2, 1999) |
| Working Capital | $11.0 million | $8.4 million (Jan 2, 1999) |
| Operating Cash Flow | $2.1 million | $3.7 million |
Margins: Gross margin was 79.6% (down from 79.0% in Q1 1998). Net profit margin was 6.8% (down from 7.4% in Q1 1998). Distributor incentives represented 44.4% of net sales.
Debt & Liquidity: The company maintains a $5.0 million line of credit expiring May 31, 1999, with no outstanding balance as of April 3, 1999. The company is in compliance with all financial covenants.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19.7% year-over-year, driven by a 42.3% increase in the total customer base (distributors and preferred customers).
- International Expansion: Sales in Australia/New Zealand grew 310.7% and the United Kingdom market (initiated Nov 1998) contributed $0.7 million. International sales now represent 45.5% of total net sales.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 33.4% to $7.2 million, primarily due to international expansion costs, increased depreciation on IT infrastructure, and higher staffing levels.
- Profitability: Despite higher sales, net earnings growth (9.9%) lagged revenue growth due to the disproportionate rise in SG&A expenses.
Outlook, Risks, and Unusual Items
- Management Commentary: Management expects continued pressure on SG&A as a percentage of sales throughout 1999 due to infrastructure build-out. They anticipate international sales will continue to grow as a percentage of total revenue.
- Related Party Transaction: On April 28, 1999, the company entered an agreement to advance up to $5.0 million to its President and CEO, Dr. Myron W. Wentz. As of April 30, $1.9 million had been advanced. Repayment will be made via the redemption and cancellation of Dr. Wentz's shares, which is anti-dilutive to other shareholders.
- Legal Proceedings: The company is defending litigation in the U.S. District Court for the District of Connecticut regarding its rights to sell the "Proflavanol" product. Motions for summary judgment are pending.
- Year 2000 Issues: The company is installing a new Enterprise Resource Planning (ERP) system expected to be complete in Q3 1999 to mitigate Year 2000 risks. They believe current systems can be mitigated but acknowledge potential operational difficulties.
- Market Risks: Significant exposure to foreign currency exchange rate fluctuations and political/economic conditions in international markets.
Investor Verification Checklist
- Verify the status and potential outcome of the Proflavanol litigation in Connecticut.
- Monitor the execution of the share redemption agreement with Dr. Wentz and its impact on share count and EPS.
- Assess the timeline and success of the new ERP system installation regarding Year 2000 compliance.
- Track the sustainability of SG&A expense growth relative to revenue as international markets mature.
- Confirm the renewal terms of the $5.0 million line of credit expiring May 31, 1999.